JOP20200315A1 - مركبات بورينون واستخدامها في معالجة السرطان - Google Patents

مركبات بورينون واستخدامها في معالجة السرطان

Info

Publication number
JOP20200315A1
JOP20200315A1 JOP/2020/0315A JOP20200315A JOP20200315A1 JO P20200315 A1 JOP20200315 A1 JO P20200315A1 JO P20200315 A JOP20200315 A JO P20200315A JO P20200315 A1 JOP20200315 A1 JO P20200315A1
Authority
JO
Jordan
Prior art keywords
compounds
salts
treatment
cancer
relates
Prior art date
Application number
JOP/2020/0315A
Other languages
English (en)
Inventor
Attilla Kuan Tsuei Ting
Frederick Woolf Goldberg
Maurice Raymond Verschoyle Finlay
Martin Richard Howard
Original Assignee
Cancer Research Tech Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Astrazeneca Ab filed Critical Cancer Research Tech Ltd
Publication of JOP20200315A1 publication Critical patent/JOP20200315A1/ar
Application granted granted Critical
Publication of JOP20200315B1 publication Critical patent/JOP20200315B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measurement Of Radiation (AREA)

Abstract

يتعلق الاختراع الحالي بصفة عامة بمركبات بالصيغة (I): (I) وأملاح مقبولة صيدلانياً منها، حيث R1، A1، A2 وA3 لها أي من المعاني المحددة في هذه الوثيقة. تتعلق المواصفة أيضاً باستخدام هذه المركبات والأملاح منها لمعالجة أو الوقاية من مرض ناتج عن DNA-PK، بما في ذلك السرطان. تتعلق المواصفة أيضاً بتركيبات صيدلانية تشتمل على هذه المركبات والأملاح؛ أطقم تشتمل على هذه المركبات والأملاح؛ طرق لتصنيع هذه المركبات والأملاح؛ مركبات وسيطة مفيدة في تصنع هذه المركبات والأملاح؛ وبطرق لمعالجة مرض ناتج عن DNA-PK، بما في ذلك السرطان، باستخدام هذه المركبات والأملاح.
JOJO/P/2020/0315A 2018-06-15 2020-12-07 مركبات بورينون واستخدامها في معالجة السرطان JOP20200315B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15
PCT/EP2019/065686 WO2019238929A1 (en) 2018-06-15 2019-06-14 Purinone compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
JOP20200315A1 true JOP20200315A1 (ar) 2020-12-07
JOP20200315B1 JOP20200315B1 (ar) 2024-04-18

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0315A JOP20200315B1 (ar) 2018-06-15 2020-12-07 مركبات بورينون واستخدامها في معالجة السرطان

Country Status (29)

Country Link
US (2) US11884671B2 (ar)
EP (1) EP3807278B1 (ar)
JP (1) JP7472044B2 (ar)
KR (1) KR102793666B1 (ar)
CN (1) CN112236431B (ar)
AR (1) AR114971A1 (ar)
AU (1) AU2019287295B2 (ar)
BR (1) BR112020025127A2 (ar)
CA (1) CA3102195A1 (ar)
CL (1) CL2020003131A1 (ar)
CO (1) CO2020015758A2 (ar)
CR (1) CR20200620A (ar)
DO (1) DOP2020000241A (ar)
EA (1) EA202190006A1 (ar)
EC (1) ECSP20080276A (ar)
ES (1) ES2931448T3 (ar)
IL (1) IL279370B2 (ar)
JO (1) JOP20200315B1 (ar)
MA (1) MA52886A (ar)
MX (1) MX2020013570A (ar)
NI (1) NI202000099A (ar)
PE (1) PE20210003A1 (ar)
PH (1) PH12020552148A1 (ar)
SG (1) SG11202012035WA (ar)
TW (1) TWI820146B (ar)
UA (1) UA126837C2 (ar)
UY (1) UY38263A (ar)
WO (1) WO2019238929A1 (ar)
ZA (1) ZA202100195B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
EP4086258A4 (en) * 2019-12-31 2023-11-29 Chengdu Baiyu Pharmaceutical Co., Ltd. PURINE DERIVATIVE AND ITS MEDICAL USE
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
TWI765640B (zh) * 2020-04-10 2022-05-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的氨基嘧啶化合物及其衍生物
MX2022013054A (es) * 2020-04-17 2022-11-09 Chengdu Baiyu Pharmaceutical Co Ltd Derivados de imidazolidinona y uso medico de los mismos.
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
AU2021346954A1 (en) * 2020-09-24 2023-05-25 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117377676B (zh) * 2021-06-29 2026-04-07 康百达（四川）生物医药科技有限公司 嘌呤衍生物的晶型及其药物组合物
WO2023036156A1 (zh) * 2021-09-07 2023-03-16 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025199376A1 (en) * 2024-03-22 2025-09-25 Padarn Therapeutics, Inc. Cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
UA109775C2 (xx) * 2009-10-29 2015-10-12 N-вмісні гетероарильні похідні як інгібітори jak3-кінази
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
MX2013010439A (es) * 2011-03-11 2014-07-09 Gilead Calistoga Llc Tratamientos combinados para neoplasias hematologicas.
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
SMT202100225T1 (it) * 2016-12-20 2021-05-07 Astrazeneca Ab Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro

Also Published As

Publication number Publication date
NI202000099A (es) 2021-09-24
AU2019287295A1 (en) 2021-02-04
ES2931448T3 (es) 2022-12-29
IL279370B1 (en) 2024-07-01
CR20200620A (es) 2021-03-09
TW202035410A (zh) 2020-10-01
AR114971A1 (es) 2020-11-11
TWI820146B (zh) 2023-11-01
CN112236431B (zh) 2024-02-13
JP2021527095A (ja) 2021-10-11
UA126837C2 (uk) 2023-02-08
US20210171525A1 (en) 2021-06-10
UY38263A (es) 2019-12-31
AU2019287295B2 (en) 2022-05-26
CO2020015758A2 (es) 2021-04-30
SG11202012035WA (en) 2021-01-28
KR20210020944A (ko) 2021-02-24
IL279370A (en) 2021-01-31
KR102793666B1 (ko) 2025-04-08
CN112236431A (zh) 2021-01-15
MA52886A (fr) 2021-04-21
CA3102195A1 (en) 2019-12-19
BR112020025127A2 (pt) 2021-03-23
US20240150355A1 (en) 2024-05-09
ECSP20080276A (es) 2021-01-29
EP3807278B1 (en) 2022-08-31
WO2019238929A1 (en) 2019-12-19
DOP2020000241A (es) 2021-04-30
IL279370B2 (en) 2024-11-01
ZA202100195B (en) 2022-08-31
MX2020013570A (es) 2021-05-27
PE20210003A1 (es) 2021-01-05
PH12020552148A1 (en) 2021-07-05
EA202190006A1 (ru) 2021-03-29
US11884671B2 (en) 2024-01-30
NZ771886A (en) 2024-07-26
CL2020003131A1 (es) 2021-04-30
JOP20200315B1 (ar) 2024-04-18
JP7472044B2 (ja) 2024-04-22
EP3807278A1 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2020007265A (es) Derivados de rapamicina.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA202192433A1 (ru) Соединения, полезные в терапии вич
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
CR20240101A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464)
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
EA202090969A1 (ru) Третичные спирты в качестве ингибиторов pi3k-
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak